

CONTENTS

PART I STAGING

CHAPTER 1	GENERAL INTRODUCTION	9
CHAPTER 2	CATHETER-ASSISTED PET/CT IMAGING OF PRIMARY BLADDER CANCER	31
CHAPTER 3	DETECTING PRIMARY BLADDER CANCER USING DELAYED PET/CT IMAGING AFTER FORCED DIURESIS	45
CHAPTER 4	IMPACT OF PET/CT ON MANAGEMENT OF PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER	59
CHAPTER 5	PET/CT AIDS STAGING AND PREDICTS MORTALITY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER	71
CHAPTER 6	PET/CT FOR MONITORING THE RESPONSE OF PELVIC LYMPH NODE METASTASES TO NEOADJUVANT CHEMOTHERAPY FOR BLADDER CANCER	85
CHAPTER 7	PROSTATE-SPARING CYSTECTOMY AND NEOBLADDER: 20 YEARS SINGLE CENTER EXPERIENCE	99
CHAPTER 8	DIFFERENCES IN HISTOPATHOLOGICAL EVALUATION OF STANDARD LYMPH NODE DISSECTIONS RESULT IN DIFFERENCES IN NODAL COUNT BUT NOT IN SURVIVAL	113
CHAPTER 9	CARBOPLATIN-BASED NEOADJUVANT CHEMOTHERAPY FOR NONORGAN-CONFINED BLADDER CANCER – A REASONABLE ALTERNATIVE FOR CISPLATIN UNFIT PATIENTS?	127
CHAPTER 10	OCCULT LYMPH NODE METASTASES IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER: INCIDENCE AFTER NEOADJUVANT CHEMOTHERAPY AND CYSTECTOMY VERSUS CYSTECTOMY ALONE	141
CHAPTER 11	INDUCTION CHEMOTHERAPY FOLLOWED BY SURGERY IN NODE POSITIVE BLADDER CANCER	157

PART II TREATMENT

PART III

MISCELLANEOUS

CHAPTER 12	EXTRAVASATION OF INTRAVESICAL CHEMOTHERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER	173
CHAPTER 13	BIOMARKERS FOR ASSESSING THERAPEUTIC RESPONSE IN BLADDER CANCER	185
CHAPTER 14	STANDAARD LYMFEEKLIERDISSECTIE BIJ BLAASCARCINOOM: SIGNIFICANTE VERSCHILLEN IN HET AANTAL GERAPPORTEERDE LYMFEEKLIEREN	201
CHAPTER 15	GENERAL DISCUSSION	213
	SUMMARY	233
	SAMENVATTING	237
	LIST OF PUBLICATIONS	243
	LIST OF AUTHORS	245
	DANKWOORD	247
	ABOUT THE AUTHOR	249